Regenity Biosciences

Regenity Biosciences is heading to IDS 2025! ? We’re excited to join the global dental community in Cologne, Germany, March 25-29, 2025, and connect with other industry leaders shaping the future of regenerative dentistry. At Regenity, we specialize in bioresorbable solutions for bone and tissue regeneration, helping clinicians achieve stronger, more predictable outcomes in implantology and periodontology. ? If you're attending IDS 2025, let’s connect to explore how our regenerative technologies can advance treatment success and elevate patient care. Reach out to Brian Marini?to schedule a meeting—we look forward to making a Material Difference together! ? #IDS2025 #Regenity #RegenerativeDentistry #DentalInnovation #BoneRegeneration #TissueRegeneration

The race to innovation is heating up, and we’re setting the pace. Meet our team at #AAOS2025 to discover how we can accelerate your R&D pipeline for regenerative technologies. Let’s push the boundaries—don’t get left behind! Reach out to?Scott Salvatoriello, Bill Messer, or Stephen Noland to set up some time to connect this week in San Diego. #RegenityBiosciences #Orthopaedic #RegenerativeMedicine #InnovationInMotion #ForTheDriven

Bringing an orthopaedic innovation to market? The right development and manufacturing partner makes all the difference. At Regenity Biosciences, we are the only CDMO with deep expertise in collagen, bioceramics and synthetic polymers—the foundation of today’s most advanced regenerative solutions. With decades of experience and a proven track record, we help medtech companies develop differentiated products with efficiency and precision—accelerating the path from concept to commercialization. Join us at AAOS 2025 to explore how our end-to-end CDMO capabilities can help you design, develop, and scale next-generation orthopaedic implants, drug delivery systems, and regenerative solutions. Let’s bring your vision to life. #AAOS2025 #RegenityBiosciences #CDMO #Orthopaedics #RegenerativeMedicine #MedicalInnovation

Meniscus injuries are among one of the most common orthopedic issues, yet traditional meniscectomies, which remove damaged tissue, can frequently lead to follow-on meniscectomy or predisposition for osteoarthritis. RejuvaKnee? is changing that.? ? RejuvaKnee? provides a scaffold for the body to regenerate its own meniscal tissue, offering a regenerative alternative to meniscectomy and representing a major leap forward in meniscal repair.? ? Watch the full video as part of our global health campaign with @Reuters: https://lnkd.in/e7pKKnfg? ? #RejuvaKnee #Meniscus #SportsMedicine #Healing #InnovationInMedicine?

Exciting news! Regenity participated in a global health campaign on Reuters showcasing how regenerative medicine is transforming healthcare. Our mission is to improve patient outcomes through advanced regenerative solutions, and this campaign highlights the innovation, impact, and leadership driving that vision forward.? ?? Watch the video and read more here: https://lnkd.in/e7pKKnfg?? #RegenityBiosciences #RegenerativeMedicine #HealthcareInnovation #Reuters?

Reflecting on a Successful #MDMES25: Innovation, Insights, and Impact As #MDMES25 comes to a close, our team is energized by the conversations, connections, and insights gained throughout the event. One of the highlights was our fireside chat on regulatory strategy as a catalyst for innovation—a dynamic conversation that underscored best practices for navigating the evolving landscape of regenerative devices. We’re proud to have contributed to this dialogue and to help shape the future of medical device development. Beyond the sessions, the networking and exchange of ideas was valuable. Connecting with peers, partners, and pioneers in the space reaffirmed the shared commitment to advancing solutions that improve patient outcomes. A huge thank you to everyone who stopped by, participated in discussions, and contributed to the success of the event. Regenity is committed to leading in this space, and we look forward to continuing the conversations that will drive the next wave of innovation. What were your key takeaways from #MDMES25? Let’s keep the discussion going! #RegenityBiosciences #RegenerativeMedicine #MedicalDevices #Innovation Sean Stevenson Peggy Hansen Jessica Swanson

? Advancing Innovation in ENT Care!??? Regenity Biosciences?announced the enrollment of the first patient in its?clinical?study?for?a new, first-of-its-kind?device-drug combination?product?to improve outcomes for sinus surgery. ENHANCE?is a prospective,?single-arm, multicenter trial?designed to investigate the safety and performance of?Regenity’s?steroid-eluting nasal dressing,?in?patients?that?have undergone endoscopic sinus surgery (ESS) for chronic sinusitis [ClinicalTrials.gov ID: NCT06642116]. This product introduces?a new category of?nasal dressings?offering localized, controlled delivery of?a?commonly used?steroid, mometasone furoate,?directly to the sinus tissue. Inserted by the physician,?the device?gradually?dissolves while?delivering a corticosteroid with anti-inflammatory properties directly to the sinus lining. #RegenityBiosciences #SinusSurgery #Innovation #ClinicalResearch #MedicalDevices Learn more here: https://lnkd.in/eK-_6YEi

Regenity and FPM Sarl to showcase GUIDOR technologies at AEEDC Dubai! ? We are excited to support our distribution partner FPM Sarl, at AEEDC, as they showcase our GUIDOR? technologies for advancing dental bone grafting! ? Visit them at Stand No. 503 to explore the unique benefits of GUIDOR? easy-graft CRYSTAL+ and CLASSIC+ technologies (not available for sale in the US).?#AEEDC #GUIDOR #MaterialDifference #Dentalinnovations #Bonegrafting

We're less than three weeks away from the Medical Device Manufacturing Excellence Summit in Austin, TX (February 16-18)! A big thank you to Executive Platforms for hosting this insightful podcast, featuring our CEO Shawn McCarthy, along with Peggy Hansen and Jessica Swanson. Tune in to hear how Regenity is pioneering the design and delivery of highly differentiated regenerative devices, helping to advance innovation in medtech with greater efficiency. Listen now! And contact Sean Stevenson to connect at MDMES!

We are delighted to announce the successful completion of the first surgery using RejuvaKnee?, a groundbreaking collagen-based meniscal implant designed to be implanted arthroscopically to reinforce and repair soft tissue injuries of the meniscus. This milestone marks a pivotal moment in the evolution of meniscal repair treatments and highlights Regenity’s commitment to advancing patient outcomes through innovative regenerative solutions. Paul Fleissner, MD, an orthopedic surgeon at the Crystal Clinic in Akron, OH, performed the surgery utilizing the RejuvaKnee? implant to treat a college-aged athlete suffering from chronic pain following a prior meniscectomy. "I believe the RejuvaKnee? implant has the potential to be a game-changer for meniscal restoration, especially for younger patients under forty seeking the most durable procedure," said Dr. Fleissner. "The device offers excellent handling properties, is user-friendly for surgeons, and serves as a convenient 'off-the-shelf' solution for those who have irreparable tears or have previously lost meniscal tissue." Learn more here: https://lnkd.in/ep2EzPPP